Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma - Related Studies

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

This study is ongoing, but not recruiting participants.

Study NCT00077532. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Melanoma (Skin)

2	Additional conditions recognized in this trial
		Melanoma

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas

4	Interventions listed in this trial
		gp100 antigen
		incomplete Freund's adjuvant
		ipilimumab

5	Additional drug interventions recognized in this trial
		Freund's Adjuvant

6	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		NCI - Center for Cancer Research-Medical Oncology
		National Cancer Institute (NCI)